Director/PDMR Shareholding

GSK PLC

11 February 2025

 

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of Ordinary Shares awarded in 2020 under the Company's 2017 Performance Share Plan and subject to an additional vesting period of two years from the normal vesting date
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	256,706.434
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-10
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2020 under the Company's 2017 Performance Share Plan and subject to an additional vesting period of two years from the normal vesting date
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.5319 .	120,653
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-10
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, GSK Global Health
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Following the vesting on 10 February 2025 of 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Deborah Waterhouse will receive a cash payment of £349,569.20 less applicable tax withholding in respect of 23,853.238 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.655	23,853.238
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-10
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Following the vesting on 10 February 2025 of 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Regis Simard will receive a cash payment of £174,784.60 less applicable tax withholding in respect of 11,926.619 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.655	11,926.619
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-10
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Following the vesting on 10 February 2025 of 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Luke Miels will receive a cash payment of £349,569.20 less applicable tax withholding in respect of 23,853.238 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.655	23,853.238
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2025-02-10
f)	Place of the transaction	N/A

 

END